Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
entities : Teva pharmaceutical industries ltd symbols : Alny save search
Advancements in Diagnosis and Treatment Fuel Rising Prevalence of Thalassemia, Driving Market to 2028
Published: 2023-08-25 (Crawled : 03:00) - prnewswire.com
GLAXF | $20.2 -14.18% 510
|
Health Technology
|
| O: 2.25%
H: 0.0%
C: 0.0%
NVS | $92.57 -0.55% 0.0% 910K
|
Health Technology
|
| O: 0.67%
H: 0.37%
C: 0.26%
GSK | $39.27 -0.83% 0.01% 2.2M
|
Health Technology
|
| O: 0.67%
H: 0.45%
C: 0.2%
SGMO | $0.4853 -5.95% -6.33% 1.7M
|
Health Technology
|
| O: -3.19%
H: 0.0%
C: 0.0%
IONS | $40.81 -0.24% -0.25% 990K
|
Health Technology
|
| O: 0.0%
H: 1.68%
C: 1.28%
EDIT | $5.56 -0.89% -0.9% 1.7M
|
Health Technology
|
| O: 0.11%
H: 1.25%
C: -0.57%
ALNY | News | $145.045 -0.19% -0.19% 400K
|
Health Technology
|
| O: -0.12%
H: 2.12%
C: 1.45%
treatment market
Regeneron and Alnylam Report Promising Data from Ongoing Phase 1 Study of ALN-HSD in NASH Patients and Healthy Volunteers
Published: 2022-09-15 (Crawled : 13:00) - biospace.com/
SNYNF | News | $92.7 -2.18% 1.4K
|
Health Technology
|
| O: 1.6%
H: 0.0%
C: -6.5%
SNY | News | $45.395 -1.55% -1.58% 4.4M
|
Health Technology
|
| O: 0.4%
H: 0.84%
C: 0.37%
REGN | $893.66 -0.84% -0.84% 450K
|
Health Technology
|
| O: -0.41%
H: 3.27%
C: 1.6%
ALNY | News | $145.045 -0.19% -0.19% 400K
|
Health Technology
|
| O: -0.9%
H: 2.16%
C: 1.01%
ongoing report nash study phase 1
Alnylam and Regeneron Report Promising Data from Ongoing Phase 1 Study of ALN-HSD in NASH Patients and Healthy Volunteers
Published: 2022-09-15 (Crawled : 12:00) - biospace.com/
SNYNF | News | $92.7 -2.18% 1.4K
|
Health Technology
|
| O: 1.6%
H: 0.0%
C: -6.5%
SNY | News | $45.395 -1.55% -1.58% 4.4M
|
Health Technology
|
| O: 0.4%
H: 0.84%
C: 0.37%
REGN | $893.66 -0.84% -0.84% 450K
|
Health Technology
|
| O: -0.41%
H: 3.27%
C: 1.6%
ALNY | News | $145.045 -0.19% -0.19% 400K
|
Health Technology
|
| O: -0.9%
H: 2.16%
C: 1.01%
ongoing report nash study phase 1
Regeneron Genetics Center Discovers Rare Mutations In The CIDEB Gene That Protect Against Liver Disease
Published: 2022-07-27 (Crawled : 22:00) - prnewswire.com
TEVJF | $12.37 -24.22% 380
|
Health Technology
|
| O: 2.86%
H: 0.0%
C: 0.0%
SNY | News | $45.395 -1.55% -1.58% 4.4M
|
Health Technology
|
| O: 0.68%
H: 0.0%
C: 0.0%
REGN | $893.66 -0.84% -0.84% 450K
|
Health Technology
|
| O: 0.17%
H: 0.53%
C: -1.11%
ALNY | News | $145.045 -0.19% -0.19% 400K
|
Health Technology
|
| O: -3.5%
H: 6.04%
C: 4.76%
rare liver disease
Gainers vs Losers
| 64% | 36% |
Top 10 Gainers
AGBA | News | $1.02 155.0% 57.94% 120M
|
Finance
ZCMD | $2.86 108.76% 52.1% 2.3M
|
Commercial Services
INVO | $1.555 104.6% 51.13% 5M
|
Health Technology
ISPC | $0.437 105.16% 49.53% 37M
|
Professional, Scientific, and T...
WLGS | News | $0.92 84.0% 45.65% 1.6M
|
OST | $0.499 21.38% 45.26% 1.9M
|
XPON | News | $3.1 60.62% 37.74% 17M
|
TIRX | $0.7 44.39% 30.74% 58M
|
BNTC | News | $6.92 44.17% 30.64% 3.5M
|
Health Technology
GGE | $0.035 19.86% 29.3% 64M
|
Your saved searches
Save your searches and get alerts when important news are released.